2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5384 Predictors of outcomes after autologous hematopoietic stem cell transplantation in complete remission for relapsed/refractory diffuse large B-cell lymphoma

Moazzam Shahzad, MD, Kashaf Awais2, Nabeeha Noor3, Muhammad Kashif Amin, MD, MSc, FACP4, Shah Rukh5, Drew R Nannini, DO, PhD6, Alma Habib, MD, MS7, Mehdi Hamadani, MD8, Joseph P McGuirk, DO9, Muhammad Umair Mushtaq, MD10
1 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 University of Kansas Medical Center, Kansas City, Kansas, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

Autologous hematopoietic cell transplantation (auto-HCT) remains standard consolidative therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who achieve complete remission (CR). Predictors of post-transplant survival and relapse in this chemosensitive population remain incompletely defined. We evaluated clinical factors associated with outcomes after auto-HCT in R/R DLBCL patients in CR.

Methods:

We performed a retrospective analysis of adults with R/R DLBCL who underwent auto-HCT in CR using Center for International Blood and Marrow Transplant Research (CIBMTR) registry data (dataset P-5958). Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan–Meier method. Univariable and multivariable Cox proportional hazards models were used for OS and PFS; Fine–Gray subdistribution hazard models were used for cumulative incidence of relapse (CIR) and non-relapse mortality (NRM). Covariates with univariable p<0.10 were considered for multivariable models.

Results:

A total of 281 patients were included. Median age at transplant was 59.4 years (range 18.2–75.6); 63% were male and 68% were White. Most patients had advanced-stage disease at diagnosis (66%), extranodal involvement (63%), and Karnofsky performance status ≥90 (57%). Median prior lines of therapy was 2 (range 2–8); 20% were primary refractory to first-line therapy and 64% had primary refractory disease or early relapse (≤12 months). Double/triple-hit status was present in 11% of patients with available data. BEAM or BEAM-like conditioning was used in 78% of transplants. With a median follow-up of 49.7 months, 3-year OS was 74.5% (95% CI 69.4–80.1), PFS 63.1% (95% CI 57.5–69.2), CIR 30.1% (95% CI 24.5–35.6), and NRM 6.8% (95% CI 3.8–9.9). On multivariable analysis, increasing age independently predicted inferior OS (aHR 1.03 per year, 95% CI 1.01–1.06, p=0.018), PFS (aHR 1.02 per year, 95% CI 1.00–1.04, p=0.015), and NRM (aSHR 1.10 per year, 95% CI 1.03–1.17, p=0.003). Extranodal involvement was independently associated with worse OS (aHR 1.80, 95% CI 1.01–2.46, p=0.047) and PFS (aHR 1.63, 95% CI 1.05–2.53, p=0.030). Primary refractory disease was independently associated with substantially higher NRM compared with late relapse (aSHR 5.30, 95% CI 1.66–16.89, p=0.005), whereas early relapse was not (aSHR 1.84, 95% CI 0.55–6.12, p=0.32). Although primary refractory disease showed a lower unadjusted CIR (SHR 0.46, 95% CI 0.23–0.93, p=0.032), no multivariable model was constructed for CIR, and this association likely reflects competing-risk bias from elevated NRM rather than favorable disease biology. Traditional high-risk features, including early relapse and double/triple-hit status, did not independently predict OS or PFS.

Conclusions:

In patients with R/R DLBCL undergoing auto-HCT in complete remission, older age and extranodal involvement were the principal determinants of inferior long-term survival, while primary refractory disease primarily increased non-relapse mortality rather than relapse. Traditional high-risk disease features did not independently predict post-transplant survival in this selected chemosensitive population. These findings support auto-HCT as effective consolidation for patients achieving CR and may inform post-transplant risk stratification.

Moazzam Shahzad, MD: No relevant conflicts of interest to declare.